Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Aerovate Therapeutics, Inc. | CHIEF COMMERCIAL OFFICER | Stock Option (Right to Buy) | 66.6K | $898K | $13.49 | Jan 22, 2024 | Direct |
Aerovate Therapeutics, Inc. | CHIEF COMMERCIAL OFFICER | Common Stock | 1.29K | $25.2K | $19.50 | Jan 22, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
AVTE | Aerovate Therapeutics, Inc. | Jan 22, 2024 | 1 | $0 | 4 | Jan 24, 2024 | CHIEF COMMERCIAL OFFICER |
AVTE | Aerovate Therapeutics, Inc. | Mar 7, 2023 | 0 | $0 | 3 | Mar 8, 2023 | Chief Commercial Officer |